Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Derks IAM"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Montironi C; Amsterdam UMC Location University of Amsterdam, Department of Experimental Immunology, Amsterdam, the Netherlands.; Amsterdam Institute for Infection and Immunity, Cancer Immunology, Amsterdam, the Netherlands.; Cancer Center Amsterdam, Cancer Immunology, Amsterdam, the Netherlands., Chen Z; Amsterdam UMC Location University of Amsterdam, Department of Experimental Immunology, Amsterdam, the Netherlands.; Amsterdam Institute for Infection and Immunity, Cancer Immunology, Amsterdam, the Netherlands.; Cancer Center Amsterdam, Cancer Immunology, Amsterdam, the Netherlands., Derks IAM; Amsterdam UMC Location University of Amsterdam, Department of Experimental Immunology, Amsterdam, the Netherlands.; Amsterdam Institute for Infection and Immunity, Cancer Immunology, Amsterdam, the Netherlands.; Cancer Center Amsterdam, Cancer Immunology, Amsterdam, the Netherlands., Cretenet G; Amsterdam UMC Location University of Amsterdam, Department of Experimental Immunology, Amsterdam, the Netherlands.; Amsterdam Institute for Infection and Immunity, Cancer Immunology, Amsterdam, the Netherlands.; Cancer Center Amsterdam, Cancer Immunology, Amsterdam, the Netherlands., Krap EA; Amsterdam UMC Location University of Amsterdam, Department of Experimental Immunology, Amsterdam, the Netherlands., Eldering E; Amsterdam UMC Location University of Amsterdam, Department of Experimental Immunology, Amsterdam, the Netherlands.; Amsterdam Institute for Infection and Immunity, Cancer Immunology, Amsterdam, the Netherlands.; Cancer Center Amsterdam, Cancer Immunology, Amsterdam, the Netherlands., Simon-Molas H; Amsterdam UMC Location University of Amsterdam, Department of Experimental Immunology, Amsterdam, the Netherlands.; Amsterdam Institute for Infection and Immunity, Cancer Immunology, Amsterdam, the Netherlands.; Cancer Center Amsterdam, Cancer Immunology, Amsterdam, the Netherlands.; Amsterdam UMC Location University of Amsterdam, Department of Hematology, Amsterdam, the Netherlands.
Publikováno v:
IScience [iScience] 2024 Mar 28; Vol. 27 (5), pp. 109640. Date of Electronic Publication: 2024 Mar 28 (Print Publication: 2024).
Autor:
Favaro F; Amsterdam UMC location University of Amsterdam, Dept. of Experimental Immunology, Meibergdreef 9, Amsterdam, the Netherlands.; Amsterdam institute for Infection and Immunity, Cancer Immunology, Amsterdam, the Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, the Netherlands.; Lymphoma and Myeloma Center Amsterdam (LYMMCARE), Amsterdam, The Netherlands.; Preclinical and Experimental Research in Thoracic Tumors (PReTT), Molecular Mechanisms and Experimental Therapy in Oncology Program (Oncobell), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908, Barcelona, Spain., Both D; Amsterdam UMC location University of Amsterdam, Dept. of Experimental Immunology, Meibergdreef 9, Amsterdam, the Netherlands.; Amsterdam institute for Infection and Immunity, Cancer Immunology, Amsterdam, the Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, the Netherlands.; Lymphoma and Myeloma Center Amsterdam (LYMMCARE), Amsterdam, The Netherlands., Derks IAM; Amsterdam UMC location University of Amsterdam, Dept. of Experimental Immunology, Meibergdreef 9, Amsterdam, the Netherlands.; Amsterdam institute for Infection and Immunity, Cancer Immunology, Amsterdam, the Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, the Netherlands.; Lymphoma and Myeloma Center Amsterdam (LYMMCARE), Amsterdam, The Netherlands., Spaargaren M; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, the Netherlands.; Lymphoma and Myeloma Center Amsterdam (LYMMCARE), Amsterdam, The Netherlands.; Amsterdam UMC location University of Amsterdam, Dept. of Pathology, Meibergdreef 9, Amsterdam, the Netherlands., Muñoz-Pinedo C; Preclinical and Experimental Research in Thoracic Tumors (PReTT), Molecular Mechanisms and Experimental Therapy in Oncology Program (Oncobell), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908, Barcelona, Spain., Eldering E; Amsterdam UMC location University of Amsterdam, Dept. of Experimental Immunology, Meibergdreef 9, Amsterdam, the Netherlands. e.eldering@amsterdamumc.nl.; Amsterdam institute for Infection and Immunity, Cancer Immunology, Amsterdam, the Netherlands. e.eldering@amsterdamumc.nl.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, the Netherlands. e.eldering@amsterdamumc.nl.; Lymphoma and Myeloma Center Amsterdam (LYMMCARE), Amsterdam, The Netherlands. e.eldering@amsterdamumc.nl.
Publikováno v:
Oncogenesis [Oncogenesis] 2023 Feb 08; Vol. 12 (1), pp. 6. Date of Electronic Publication: 2023 Feb 08.
Autor:
Leeksma AC; Department of Hematology, Amsterdam University Medical Centers, University of Amsterdam, The Netherlands.; Department of Experimental Immunology, Amsterdam University Medical Centers, University of Amsterdam, The Netherlands.; Lymphoma and myeloma center Amsterdam (LYMMCARE), Cancer Center Amsterdam (CCA) and Amsterdam Infection and Immunity Institute (AIII), The Netherlands., Derks IAM; Department of Experimental Immunology, Amsterdam University Medical Centers, University of Amsterdam, The Netherlands.; Lymphoma and myeloma center Amsterdam (LYMMCARE), Cancer Center Amsterdam (CCA) and Amsterdam Infection and Immunity Institute (AIII), The Netherlands., Garrick B; Translational Research, Bristol Myers Squibb, San Francisco, CA, USA., Jongejan A; Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam University Medical Centers, University of Amsterdam, The Netherlands., Colombo M; Bristol Myers Squibb's Center for Innovation and Translational Research Europe (CITRE), Seville, Spain., Bloedjes T; Department of Pathology, Amsterdam University Medical Centers, Lymphoma and Myeloma Center Amsterdam (LYMMCARE), University of Amsterdam, The Netherlands., Trowe T; Translational Research, Bristol Myers Squibb, San Francisco, CA, USA., Leisten JC; Discovery, Bristol Myers Squibb, San Diego, CA, USA., Howarth M; Translational Research, Bristol Myers Squibb, San Francisco, CA, USA., Malek M; Translational Research, Bristol Myers Squibb, San Francisco, CA, USA., Mortensen DS; Discovery, Bristol Myers Squibb, San Diego, CA, USA., Blease K; Discovery, Bristol Myers Squibb, San Diego, CA, USA., Groza MC; Discovery, Bristol Myers Squibb, San Diego, CA, USA., Narla RK; Discovery, Bristol Myers Squibb, San Diego, CA, USA., Loos R; Bristol Myers Squibb's Center for Innovation and Translational Research Europe (CITRE), Seville, Spain., Kersten MJ; Department of Hematology, Amsterdam University Medical Centers, University of Amsterdam, The Netherlands., Moerland PD; Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam University Medical Centers, University of Amsterdam, The Netherlands., Guikema JEJ; Department of Pathology, Amsterdam University Medical Centers, Lymphoma and Myeloma Center Amsterdam (LYMMCARE), University of Amsterdam, The Netherlands., Kater AP; Department of Hematology, Amsterdam University Medical Centers, University of Amsterdam, The Netherlands.; Lymphoma and myeloma center Amsterdam (LYMMCARE), Cancer Center Amsterdam (CCA) and Amsterdam Infection and Immunity Institute (AIII), The Netherlands., Eldering E; Department of Experimental Immunology, Amsterdam University Medical Centers, University of Amsterdam, The Netherlands.; Lymphoma and myeloma center Amsterdam (LYMMCARE), Cancer Center Amsterdam (CCA) and Amsterdam Infection and Immunity Institute (AIII), The Netherlands., Filvaroff EH; Translational Research, Bristol Myers Squibb, San Francisco, CA, USA.
Publikováno v:
Molecular oncology [Mol Oncol] 2023 Feb; Vol. 17 (2), pp. 284-297. Date of Electronic Publication: 2022 Dec 16.
Autor:
Leeksma AC; Department of Hematology, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam, Netherlands.; Department of Experimental Immunology, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam, Netherlands.; Lymphoma and Myeloma Center Amsterdam (LYMMCARE), Cancer Center Amsterdam (CCA) and Amsterdam Infection and Immunity Institute (AIII), Amsterdam, Netherlands., Derks IAM; Department of Experimental Immunology, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam, Netherlands.; Lymphoma and Myeloma Center Amsterdam (LYMMCARE), Cancer Center Amsterdam (CCA) and Amsterdam Infection and Immunity Institute (AIII), Amsterdam, Netherlands., Kasem MH; Translational Functional Cancer Genomics, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany., Kilic E; Department of Ophthalmology and Clinical Genetics Erasmus MC, Rotterdam, Netherlands., de Klein A; Department of Ophthalmology and Clinical Genetics Erasmus MC, Rotterdam, Netherlands., Jager MJ; Department of Ophthalmology, LUMC, Leiden, Netherlands., van de Loosdrecht AA; Department of Hematology, Amsterdam University Medical Centers, Location VUMC, Amsterdam, Netherlands., Jansen JH; Laboratory of Hematology, Department Laboratory Medicine, Radboud University Medical Center, Nijmegen, Netherlands., Navrkalova V; Center of Molecular Biology and Gene Therapy, Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Center of Molecular Medicine, CEITEC, Masaryk University, Brno, Czechia., Faber LM; Department of Internal Medicine, Rode Kruis Ziekenhuis, Beverwijk, Netherlands., Zaborsky N; Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria.; Department of Internal Medicine III with Haematology, Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Salzburg, Austria.; Department of Internal Medicine III with Haematology, Cancer Cluster Salzburg, Salzburg, Austria., Egle A; Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria.; Department of Internal Medicine III with Haematology, Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Salzburg, Austria.; Department of Internal Medicine III with Haematology, Cancer Cluster Salzburg, Salzburg, Austria., Zenz T; Department of Oncology and Haematology, University Hospital and University of Zurich, Zurich, Switzerland., Pospisilova S; Center of Molecular Biology and Gene Therapy, Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Center of Molecular Medicine, CEITEC, Masaryk University, Brno, Czechia., Abdel-Wahab O; Human Oncology and Pathogenesis Program and Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States., Kater AP; Department of Hematology, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam, Netherlands.; Department of Experimental Immunology, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam, Netherlands., Eldering E; Department of Experimental Immunology, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam, Netherlands.; Lymphoma and Myeloma Center Amsterdam (LYMMCARE), Cancer Center Amsterdam (CCA) and Amsterdam Infection and Immunity Institute (AIII), Amsterdam, Netherlands.
Publikováno v:
Frontiers in oncology [Front Oncol] 2021 Jan 29; Vol. 10, pp. 609409. Date of Electronic Publication: 2021 Jan 29 (Print Publication: 2020).
Autor:
Martens AWJ; Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam UMC, Amsterdam, The Netherlands.; Department of Hematology, Cancer Center Amsterdam and Lymphoma and Myeloma Center Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands., Janssen SR; Department of Hematology, Cancer Center Amsterdam and Lymphoma and Myeloma Center Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands., Derks IAM; Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam UMC, Amsterdam, The Netherlands., Adams Iii HC; Janssen Pharmaceutical Companies of Johnson and Johnson, Philadelphia, Pennsylvania, USA., Izhak L; Janssen Pharmaceutical Companies of Johnson and Johnson, Philadelphia, Pennsylvania, USA., van Kampen R; Department of Internal Medicine, Zuyderland Medical Centre Heerlen, Heerlen, The Netherlands., Tonino SH; Department of Hematology, Cancer Center Amsterdam and Lymphoma and Myeloma Center Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands., Eldering E; Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam UMC, Amsterdam, The Netherlands., van der Windt GJW; Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam UMC, Amsterdam, The Netherlands.; Department of Hematology, Cancer Center Amsterdam and Lymphoma and Myeloma Center Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands., Kater AP; Department of Hematology, Cancer Center Amsterdam and Lymphoma and Myeloma Center Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands a.p.kater@amsterdamumc.nl.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2020 Jun; Vol. 8 (1).
Autor:
Wensveen FM; Department of Experimental Immunology, Academic Medical Center, Meibergdreef 8, 1105 AZ, Amsterdam, The Netherlands. felix.wensveen@gmail.com., Geest CR; Department of Experimental Immunology, Academic Medical Center, Meibergdreef 8, 1105 AZ, Amsterdam, The Netherlands., Libregts SFWM; Department of Experimental Immunology, Academic Medical Center, Meibergdreef 8, 1105 AZ, Amsterdam, The Netherlands., Derks IAM; Department of Experimental Immunology, Academic Medical Center, Meibergdreef 8, 1105 AZ, Amsterdam, The Netherlands., Ekert PG; Division of Cell Signaling and Cell Death, The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Melbourne, VIC, Australia., Labi V; Division of Developmental Immunology, BIOCENTER, Innsbruck Medical University, Innrain 80-82, 6020, Innsbruck, Austria., Villunger A; Division of Developmental Immunology, BIOCENTER, Innsbruck Medical University, Innrain 80-82, 6020, Innsbruck, Austria., Nolte MA; Department of Experimental Immunology, Academic Medical Center, Meibergdreef 8, 1105 AZ, Amsterdam, The Netherlands.; Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory AMC/UvA, Amsterdam, The Netherlands., Eldering E; Department of Experimental Immunology, Academic Medical Center, Meibergdreef 8, 1105 AZ, Amsterdam, The Netherlands.
Publikováno v:
Apoptosis : an international journal on programmed cell death [Apoptosis] 2013 Nov; Vol. 18 (11), pp. 1306-1318.